Introduction {#s02}
============

Aging is widely held to be the consequence of the accumulation of cellular damage over time ([@bib69]). In humans, aging is marked by declining tissue function and increased susceptibility to diseases such as cancer, diabetes, cardiovascular disease, dementia, arthritis, sarcopenia, and renal dysfunction. Aging-associated diseases and phenotypes frequently manifest on the tissue level yet have their roots in molecular and cellular damage ([@bib69]).

Most aging research is motivated by the need to understand the process of aging in humans. However, studying aging requires observing and perturbing molecules, cells, tissues, and systems in organisms over time---requirements that are not feasible in humans. Instead, aging is studied in model systems, each of which balances a desire for biological relevance on one hand and practicality on the other. Thus, most models of aging suffer from key limitations depending on where on this spectrum they lie. Organoid culture, especially human organoid culture, has the potential to address many of the limitations of traditional aging models. By providing organotypic structure in an in vitro model, organoids enable the study of aging in tissues in a higher-throughput, experimentally accessible manner. These potential advantages may be particularly useful for studying emergent signs of aging at the tissue level, clearing the way for future human therapies.

What is an organoid? {#s03}
--------------------

An organoid is a miniature, simplified organ that recreates physiological 3D tissue structure and cellular composition in vitro. Examples include a variety of 3D in vitro culture systems: cultured tissue fragments, tissues reconstituted from cultured cells, and tissues grown from stem cells, usually in the presence of ECM protein. In this perspective, we have broadly included examples and influences from several different organotypic culture systems. The use of organoids reflects the philosophy that the structure and composition of a tissue is relevant to its function ([@bib111]). In practice, organoids are characterized by some if not all of the following features:

• A physiologically relevant microenvironment

• Cells derived from primary tissues, primary cells, or stem cells, rather than immortalized cell lines

• Cells correctly organized with respect to one another and their ECM

• Multiple cell types from the original organ

Models of aging {#s04}
===============

The spectrum of aging models {#s05}
----------------------------

The trade-off between relevance to humans and ease of experimentation is a limitation in any model, particularly when seeking to develop interventions to limit the effects of human aging. Organoids provide a powerful and physiologically relevant means to perform in vitro experiments on tissue and on human tissue in particular.

Nonhuman organisms and traditional cell culture have been invaluable tools for the study of fundamental aging processes, including the Nobel Prize-winning mechanisms of telomere regulation and DNA repair ([@bib107]; [@bib41]; [@bib66]). However, model organisms may age in ways not applicable to humans. For example, *Caenorhabditis elegans* has a dauer stage, a stress- and aging-resistant larval form. Induction of dauer-like states may alter lifespan with questionable correlation to human aging ([@bib76]). In mice, the most common mammalian model organism, important features that affect aging, such as immune response, DNA repair, telomerase regulation, and telomere length, differ significantly between mice and humans ([@bib104]; [@bib110]). Even naked mole rats and blind mole rats, two rodents both renowned for their sevenfold-longer lives than laboratory mice, owe their longevity to differing molecular mechanisms ([@bib6]). Thus, different species, even within the same order, have developed distinct mechanisms for controlling lifespan and health span in relatively brief evolutionary time. These differences have practical implications. Some of the most prominent diseases of human aging, such as epithelial cancers, cardiovascular disease, osteoporosis, and Alzheimer's disease, are rare or nonexistent in aged mice, who instead predominantly suffer from mesenchymal cancers ([@bib104]; [@bib126]). Consequently, interventions that reduce susceptibility to human age-related diseases may not affect mouse lifespan, and vice versa.

Ultimately, studies in humans are necessary to validate therapies for human aging, but ethical, logistical, and financial challenges render routine human aging studies infeasible. A widely practiced alternative is cell culture, but the correlations to human aging may be weak because of the lack of physiological context. Many signs of aging, namely those that manifest at the tissue and organ level, may be best represented by a more complex system. These signs of aging include a breakdown in tissue homeostasis, stem cell dysfunction, and susceptibility to tissue-specific diseases and cancer ([@bib69]).

Although more technically challenging than traditional cell culture, organoids provide increased relevance to human health via a microenvironment supportive of tissue-specific function and physiological cell--cell and cell--matrix interactions. These factors contribute to increased viability of difficult-to-culture cells, including primary cells and prostate tumors ([@bib38]). Moreover, 3D culture improves cell type--specific function and gene expression in cells such as chondrocytes, hepatocytes, and mammary and kidney epithelial cells ([@bib14]; [@bib3]; [@bib21]; [@bib111]). As a result, organoids may be useful for modeling age-related declines in tissue-specific function, such as chondrocyte matrix deposition ([@bib7]). Furthermore, age-related pathologies intrinsically linked to the ECM, such as osteoarthritis, are well-suited to study in a 3D system ([@bib70]). Organoids may be the most practical way to perform aging experiments at this level of complexity, particularly on human tissues.

Practical experiments with organoid models {#s06}
------------------------------------------

Organoids provide a practical alternative to whole-organism studies in mammals. Patient-derived organoids have been scaled to high-throughput screens against cystic fibrosis and cancer, which would be cost-prohibitive in mice or humans ([@bib31]; [@bib98]; [@bib109]). Demonstrating the scalability and high-throughput potential of organoids, [@bib98] developed patient-derived tumor organoids for screening a library of \>100 drugs at different concentrations and combinations, and [@bib30] screened nearly 5,000 proteins for their effects on basal cell fate in human lung organoids.

Improved throughput is made possible not only by larger sample sizes but also simpler assays. Some molecular signs of aging, such as protein aggregation, oxidation, and glycation, can be assayed by nondestructive, high-throughput microscopy ([@bib77]; [@bib26]; [@bib54]). Organoids are far more amenable to live-cell imaging than whole organisms, such as mice, and can complement mouse studies with imaging and perturbations that would be otherwise impractical. High-resolution live imaging of development, stem cell dynamics, and cancer invasion has been demonstrated in several organoid systems ([@bib108]; [@bib90]).

Finally, manipulating microenvironmental cues and specific cell populations is more straightforward in organoids than model organisms. Organoids are typically embedded in a matrix of the investigators' choice, allowing for increased control over its source, composition, and mechanical properties. Cells acquired from tissue can be sorted, modified to delete or express specific genes, and expanded before assembly into organoids, allowing investigators to build organoids using defined building blocks from the bottom up. These organoids enable otherwise infeasible studies, such as tissues bearing gene knockouts that would be embryonically lethal. Additionally, this strategy allows the construction of organoids composed of specific proportions of cell subpopulations. For example, [@bib108] assembled intestinal organoids from stem cells with or without Paneth cells to identify Paneth cells as essential components of the intestinal stem cell (ISC) niche, a result previously obscured by incomplete lineage ablation. Moreover, viral vectors or transfection allows genetic manipulation of organoids with far less time and expense than developing a transgenic mouse ([@bib57]). As a result, organoid approaches greatly enhance our capacity to study specific cell populations, phenotypes, and mutations within the context of a tissue. Organoid models of aging are in their earliest stages, but promising work, discussed in this perspective, has demonstrated their potential applicability to aging research.

Studying aging in organoids {#s07}
===========================

Molecular and cellular processes {#s08}
--------------------------------

The genome can be damaged through several mechanisms, leading to the acquisition of genetic and epigenetic changes with age. DNA damage activates repair pathways but can also trigger mutations, apoptosis, or senescence. These outcomes can lead to aberrant behavior and deleterious effects on neighboring cells, such as inflammatory senescence-associated signaling ([@bib97]). Epigenetically, aging cells acquire regional hyper- and hypomethylation, as well as increased variance in epigenetic marks ([@bib53]). These cell-intrinsic aspects of aging are preserved in primary cells and tissue-derived organoids ([@bib17]).

Glycation, oxidation, and misfolding are foremost among molecular damage to proteins during aging. In particular, ECM proteins such as collagen, elastin, and crystallin are susceptible to nonenzymatic glycation, leading to stiffening of the ECM ([@bib112]). Age-associated glycation, as well as altered structure, composition, and cross-linking of the ECM, has been associated with functional declines in a variety of tissues ([@bib99]). As matrix is a major component of organoid culture, organoids are a natural model for the effects of aged ECM on tissue function.

Organoid assays can enable researchers to experimentally link aging-associated changes in ECM structure to functional consequences. ECM substrates and gels for cell culture have been isolated from human and animal tissue ([@bib132]; [@bib142]; [@bib93]). Decreased cell proliferation and stem cell function have been observed on matrices derived from older donors, including Bruch's membrane and cardiac and skeletal muscle ECM ([@bib42]; [@bib134]; [@bib115]). More complex phenotypes can also be linked to ECM source by using organoid models. The Schedin group ([@bib71]) has shown that ECM from rats in different reproductive states can instruct morphogenesis and invasion of human mammary and breast cancer organoids. In addition, several groups have experimentally modified the ECM via advanced glycation end product--mediated cross-linking to mimic ECM aging, demonstrating aging phenotypes such as skin and cartilage stiffening and increased invasiveness ([@bib129]; [@bib95]; [@bib105]).

Chemical damage can also lead to degradation and aggregation of proteins and other biomolecules, such as lipids. Protein damage accumulates in the form of carbonylation, fragmentation, and cross-linking, whereas lipid peroxidation compromises membranes and leads to the accumulation of oxidized fatty acids. Oxidation products not only have reduced function but are also prone to cross-linking. Together with misfolding, age-associated protein oxidation results in proteolysis-resistant aggregates both intra- and extracellularly. This feature is highly conserved across species; one of the most universal signs of aging is the accumulation of intracellular lipofuscin lipid-protein aggregates ([@bib54]). Although their causal role in pathogenesis is disputed, protein and lipid-protein aggregates are prominently associated with central nervous system dysfunction, such as the infamous tangles, amyloids, and Lewy bodies in neurodegenerative disease, and the retinal drusen in age-related macular degeneration ([@bib29]; [@bib22]). These late-stage manifestations of neurodegenerative pathology may be more apparent in 3D culture than in traditional cell culture, where secreted proteins diffuse freely into culture media rather than accumulate near cells. In a human stem cell--derived model of familial Alzheimer's disease, 3D culture was found to not only improve neuronal maturation but also promote tauopathy though the accumulation of β-amyloid aggregates in the ECM, observations that did not occur in 2D culture or mice ([@bib27]). Similarly, scaffold-free 3D neural organoids, but not 2D culture, were shown to accumulate amyloid aggregates and model tauopathy. Significantly, these signs of human neurodegeneration were spontaneous in patient-derived organoids but are often only observed in mice after the expression of multiple human transgenes ([@bib103]).

Tissue-level processes {#s09}
----------------------

At the tissue level, accumulated molecular damage can manifest in a variety of ways. These include changes in tissue function, susceptibility to cancer and other diseases, changes in stem cell function, and alterations in the immune system ([@bib5]; [@bib69]; [@bib16]). Encouragingly, a variety of organoid models have already been explored to study aspects of each of these age-related phenomena.

One feature of aging is a progressive decline in physiological function. Various signs of aging, such as lower glomerular filtration rate, reduced cardiac output, and increased susceptibility to disease, can often be tied to tissue-specific changes that may be more apparent in 3D tissues than 2D culture. For example, a semi-enclosed cardiac organoid chamber allows for the measurement of pressure and ejection fraction ([@bib61]). Barrier function can be measured across a kidney- or neural-endothelial interface ([@bib128]), which could be used to model aging-associated declines in glomerular filtration rate and blood-brain barrier function ([@bib120]; [@bib35]). Additionally, gastrointestinal organoids have been used extensively to study host-microbe interactions ([@bib11]; [@bib36]). They would be well-suited to studying the aging microbiome and age-related susceptibility to disease caused by ordinarily asymptomatic microbes, such as *Clostridium difficile* ([@bib50]; [@bib46]). Age-associated changes in circadian rhythm may also be modeled in organoids, considering that intestinal explants and stem cell--derived organoids, but not 2D culture, have been demonstrated to spontaneously produce robust, synchronized circadian oscillations ([@bib85]; [@bib82]). In general, organotypic cultures can represent more complex and accurate phenotypes than 2D culture and are thus ideal for modeling their decline in aging.

Organoids are widespread models for cancer progression that have been used to study tumor-initiating mutations and processes, such as cancer cell dissemination ([@bib64]; [@bib90]). A natural extension of this work would be to use organoids from donors of different ages to understand how normal, aged tissue responds to in vitro oncogenic transformation. For example, transformed human mammary epithelial cells develop phenotypes dependent on donor age. Aged cells more frequently adopted a luminal-like phenotype and expressed estrogen receptor α in organoid culture, suggesting that age is a determinant of cancer subtype ([@bib62]). In addition, organoid culture permits study of the tumor microenvironment, including neighboring cells and the ECM. Age-related changes to the microenvironment may play a role in altered susceptibility to cancer. Experimental glycation of the ECM increased invasiveness and decreased epithelial differentiation in nonmalignant prostate acini ([@bib105]). Similarly, the accumulation of senescent cells with age may exert tumor-promoting effects on neighboring cells. By coculturing fibroblasts with nonmalignant mammary organoids, [@bib97] demonstrated that senescent fibroblasts secreted factors that increased invasion and proliferation, and decreased epithelial differentiation.

Organoids are excellent models for stem cell maintenance and tissue repair, because organoids can recreate in vitro the minimal unit of a stem cell niche: cells and ECM in an organotypic structure ([@bib84]). Stem cell exhaustion, or reduced proliferation and biased differentiation of stem cells, contributes to aging in several tissues, and stem cell function is a common readout in aging studies ([@bib18]; [@bib96]; [@bib39]). For example, mouse intestinal organoids have been used to study the proliferation and differentiation of ISCs in the context of aging research. In one study of ISC function, which declines with age, [@bib86] used organoids from aged mice to determine that the aged ISC niche was deficient in Wnt signaling. Exogenous Wnt3a supplementation in organoid culture was sufficient to restore organoid formation and lobe growth of aged ISCs. Other investigators have used organoid-formation assays to study caloric restriction, an intervention shown to have anti-aging effects in several model organisms, including nonhuman primates ([@bib75]). By combining the Paneth cells and ISCs of ad libitum-fed and calorie-restricted mice, [@bib140] demonstrated that Paneth cells from calorie-restricted mice were responsible for increasing ISC organoid formation and size. The capacity to separate and perturb the contributions of individual niche components, such as growth factors and accessory cells, during aging and anti-aging interventions in a rapid, systematic manner is an important advantage that organoids provide over model organisms.

Aging of the immune system is characterized by changing proportions of immune cells, declining innate immune function, and increased chronic inflammation ([@bib5]). To study how these factors intersect with age-associated diseases such as cancer and osteoarthritis, aging researchers can take advantage of existing methods for studying the effects of immune cell co-culture and pro-inflammatory stimuli in organoids. For example, co-culture of primary mouse mammary epithelial organoids and immune cells demonstrated how immune cells regulate branching morphogenesis ([@bib100]). Systemic inflammation has also been studied in organoids by adding inflammatory cytokines or antiinflammatory drugs to the culture medium. Anti-inflammatory treatment of intestinal organoids suppressed the senescence-associated inflammatory response and reduced inflammation-mediated tumorigenesis ([@bib101]). [@bib117] used both cytokines and macrophage-conditioned media to simulate immune involvement in a 3D human chondrocyte model of osteoarthritis. In response to inflammation, the cartilage scaffolds demonstrated phenotypic features of early osteoarthritis, such as increased and atypical matrix synthesis and degradation. These examples highlight systems that integrate organoids with immune cells and inflammatory cytokines.

Sourcing organoids {#s10}
==================

Organoids can be derived from several sources, most notably primary cells and tissue or pluripotent stem cells (PSCs). Cell lines are less suitable sources for most applications of organoids to aging research, because of immortalization, evasion of cellular senescence, or tumor origins. In contrast, tissues from donors of different ages are a more suitable model of the phenotypes of aging. These samples are becoming more readily available to the basic science research community. A handful of untransformed primary human cell types and tissues, such as keratinocytes, stromal and dermal fibroblasts, and mammary epithelial cells, are available from cell banks. Skin, blood, marrow, fat, breast, and muscle are relatively abundant tissues that can be acquired from healthy donors undergoing elective surgery. In addition, primary human material can be obtained from pathologically normal tumor-peripheral tissue, surgical discards, tissues ineligible for transplant, and trimmings from transplanted tissues ([@bib9]).

Fresh, primary tissue explants or fragments can be cultured with minimal processing, often retaining multiple cell types and the surrounding donor-derived ECM and stroma ([Fig. 1 A](#fig1){ref-type="fig"}; [@bib121]; [@bib90]; [@bib65]). Some, such as arteries, skin, and central nervous system, are typically cultured as thin slices; alternatively, organoids may be derived from fragments of digested minced tissue. Both strategies maintain original tissue structure, minimize disruption to cell state, and may include ECM and accessory cells. The maintenance of intact paracrine signaling networks contributes to the overall function of tissue fragment-derived organoids. For example, the stromal compartment in intestinal organoids can maintain the stem cell niche without exogenous growth factors ([@bib94]). Similarly, human mammary organoids retaining stromal and ECM elements maintain hormone responsiveness and proliferate without exogenous growth factors ([@bib121]). These organoids represent the most physiologically relevant in vitro models and can be particularly valuable for studying complex, intercellular signaling networks in aging tissue. However, sample size and tissue types are limited, and it can be difficult to specifically perturb one component or cell type in the system.

![**Types of organoids. (A)** Tissue fragments and explants are generated from native tissue with little disruption to cell and ECM organization and no intermediate period in 2D culture. This limits total sample size and manipulability but is unmatched in mimicking the original tissue. **(B)** Reconstituted organoids are assembled in vitro from cultured or sorted cells. This permits cell expansion and modular assembly of components. However, some subpopulations or phenotypes, such as senescent and hormone-responsive cells, may be lost during culture. **(C)** Stem cell--derived organoids are differentiated from multipotent adult tissue stem cells or PSCs under the appropriate differentiation and maintenance conditions. PSCs specifically can generate rare tissue and cell types, but have limited maturity and lose the hallmarks of aging.](JCB_201709054_Fig1){#fig1}

In contrast, primary human cells can be dissociated, optionally expanded in culture, and then reconstituted into organoids. These reconstituted organoids allow for expanded cell numbers and considerably more control over constituent cells and ECM, including the opportunity to perturb specific components ([Fig. 1 B](#fig1){ref-type="fig"}). Although tissue composition and cell state change rapidly on 2D culture, suitable conditions for preserving lineage-specific markers during expansion have been identified in a variety of tissues, including keratinocytes, fibroblasts, and mammary and lung epithelial cells ([@bib135]; [@bib114]; [@bib9]). Lung epithelial cells can be expanded in culture and give rise to branched bronchial or alveolar organoids ([@bib9]). Human mammary epithelial cells are a notable aging resource established from surgical discards of donors of different ages and disease status, including healthy women and cancer patients ([@bib114]). Nonimmortal mammary epithelial cells can be expanded in vitro for several passages, retain transcriptional signatures of their source tissue, and recapitulate the bilayered structure of the mammary gland in reconstituted organoids ([@bib39]; [@bib23]). One caveat is that expansion in culture selects for proliferative cells, potentially excluding cells with short telomeres, terminally differentiated nonproliferating cells, and cells undergoing senescence. Furthermore, 2D culture also causes loss of cell type--specific transcriptional profiles; some of this dedifferentiation can be reversed or ameliorated on transitioning to organotypic culture ([@bib21]).

Primary tissue is also a source of multipotent adult tissue stem cells that can generate organoids in the presence of specific growth factors; stem cell--derived organoids are also generated from PSCs ([Fig. 1 C](#fig1){ref-type="fig"}). Organoids from multiple epithelial tissues, including stomach, small intestine, colon, liver, pancreas, breast, and prostate, have been expanded from single primary stem or progenitor cells ([Table 1](#tbl1){ref-type="table"}). However, an issue with this method is that their maintenance requires the inclusion of stem cell niche--maintaining soluble factors, which may obscure phenotypes of aging that originate in growth factor signaling ([@bib19]; [@bib86]). In contrast, PSCs, including induced PSCs (iPSCs) and embryonic stem cells allow for a greater range of key human tissue types than can be practicably supplied by surgical discards, notably brain and cardiac muscle. These organoids frequently contain multiple cell types and self-organizing tissue structures that recapitulate embryonic development. For example, human iPSC-derived brain organoids have been used to model early stage and developmental disorders ([@bib102]) and could become excellent models for neurodegenerative diseases such as Alzheimer's disease. [@bib103] demonstrated that iPSC organoids derived from patients with familial Alzheimer's disease develop robust pathology, including amyloid aggregation, hyperphosphorylated tau protein, and endosome abnormalities. Caution must be exercised when applying stem cell studies to aging research. Although familial disease--linked mutations are widely studied, genetic disease may differ mechanistically from sporadic, age-related disease. Furthermore, PSCs begin in a fetal-like state and require additional maturation. Many hallmarks of aging, aside from somatic mutations, are reverted on iPSC reprogramming, including DNA damage foci, epigenetic marks, oxidative damage, senescence markers, and telomere length ([@bib49]; [@bib28]).

###### Examples of rodent and human tissues cultured as organoids

  Tissue                                                         Type           Examples                                       
  -------------------------------------------------------------- -------------- ------------------- -------------------------- ---------------------------------------------------------------
  Central nervous system: brain, retina                          Human, rat     Rat                 hiPSC, hESC                [@bib139]; [@bib127]; [@bib44]; [@bib34]; [@bib102]; [@bib74]
  Gastrointestinal: esophagus, stomach, small intestine, colon   Human, mouse                       Human, mouse, hPSC, mESC   [@bib94]; [@bib10]; [@bib108]; [@bib11]; [@bib92]; [@bib65]
  Pancreas                                                       Human, mouse                       Human, mouse, hiPSC        [@bib51]; [@bib73]; [@bib19]; [@bib48]
  Liver                                                          Human, mouse   Human               Human, mouse, hiPSC        [@bib79]; [@bib52]; [@bib119]; [@bib19]
  Kidney                                                         Mouse          Human, mouse        hiPSC, hESC                [@bib3]; [@bib25]; [@bib37]; [@bib83]
  Lung                                                           Human, mouse   Human, mouse        hiPSC, mouse               [@bib81]; [@bib137]; [@bib8]; [@bib33]; [@bib45]
  Muscle: skeletal, cardiac                                                     Human, rat, mouse   hiPSC                      [@bib61]; [@bib72]; [@bib125]
  Skin                                                           Human          Human                                          [@bib116]; [@bib32]
  Cartilage                                                      Human          Human               hMSC                       [@bib113]; [@bib21]; [@bib70]; [@bib15]
  Artery                                                         Rat            Human, mouse                                   [@bib13]; [@bib59]
  Mammary gland                                                  Human, mouse   Human               Human                      [@bib130]; [@bib67]; [@bib121]; [@bib90]
  Prostate                                                       Human          Human, rat          Human, mouse               [@bib89]; [@bib60]; [@bib55]
  Ovary, endometrium                                             Human          Human                                          [@bib58]; [@bib124]
  Thyroid                                                        Human                              mESC                       [@bib122]; [@bib1]

Organoid culture has now been extended to a variety of tissues, including many from adult human primary tissue or cells. h, human; m, mouse; MSC, mesenchymal stem cell.

Outlook {#s11}
=======

Advances in organotypic culture techniques ultimately seek to obtain relevant phenotypes in vitro. Remarkable progress has been made in developing organoid techniques and culture systems, but several limitations remain to be addressed or validated. Furthermore, there are many opportunities to improve on the reproducibility and complexity of organoids, particularly by the inclusion of tissue engineering and microfluidics. These areas of current research are summarized in [Table 2](#tbl2){ref-type="table"}.

###### Summary of current limitations and areas for development in organoid culture for aging

  Goals                                                                                                                 Approaches                                                                                                   Challenges
  --------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------
  Increase developmental maturity of pluripotent stem cell--derived organoids                                           Long-term culture ([@bib91]; [@bib118]; [@bib125])                                                           Stem cells are highly sensitive to culture conditions, impeding robust protocols
                                                                                                                        In vivo maturation ([@bib51]; [@bib133]; [@bib119])                                                          
                                                                                                                        Mechanical or electrical conditioning of muscle and cartilage ([@bib106])                                    
                                                                                                                        Improved culture conditions and differentiation protocols                                                    
                                                                                                                        Acceleration by small molecules ([@bib24])                                                                   
  Source culturable, age-varied human cells                                                                             Surgical discards from elective surgery, transplant trimmings, and tissue peripheral to tumors               Hard to source certain tissues, especially healthy, culturable adult cells
                                                                                                                                                                                                                                     Cells adapt to culture and are not infinitely renewable
                                                                                                                                                                                                                                     Nontumor peripheral tissue may differ from healthy tissue
  In vitro aging to model the effects of specific age-related lesions and provide a source of artificially aged cells   Induced senescence by DNA damage or environmental stress ([@bib20]; [@bib97]; [@bib87])                      Controversial which treatments best phenocopy aging
                                                                                                                        Long-term culture ([@bib32])                                                                                 
                                                                                                                        Progeria mutations ([@bib68]; [@bib141]; [@bib80])                                                           
                                                                                                                        Direct reprogramming of aged cells ([@bib78])                                                                
  Mimic the effects of the aged ECM in vitro                                                                            ECM from aged donors ([@bib42]; [@bib134]; [@bib115])                                                        Controversial which treatments best phenocopy aging
                                                                                                                        Glycation crosslinking ([@bib105])                                                                           ECM extraction from tissues can alter its mechanical properties, microstructure, and composition
                                                                                                                        Enzymatic crosslinking ([@bib63])                                                                            
  Develop aging-relevant experimental readouts                                                                          Epigenetic clock ([@bib43]; [@bib49])                                                                        Unclear which signs of aging are most important
                                                                                                                        Mutational analysis ([@bib17])                                                                               Require signs of aging that change appreciably across the span of an experiment
                                                                                                                        Protein/DNA oxidation                                                                                        
                                                                                                                        Protein aggregation                                                                                          
                                                                                                                        Tissue-specific functional assays                                                                            
  Long-term maintenance of organoids in a stable, growth-arrested state                                                 Improved culture media                                                                                       Relatively few published maintenance conditions
                                                                                                                        Improved ECM and bioreactors                                                                                 Vetting culture conditions is lengthy
  Complete modeling of whole organs and physiological systems                                                           Co-culture with immune cells, stromal cells, and microbiome bacteria ([@bib97]; [@bib36]; [@bib100])         Few good techniques for sophisticated organoid construction
  Increase throughput and reproducibility                                                                               Vascularization ([@bib4])                                                                                    Powerful techniques are often cumbersome and low-throughput
                                                                                                                        Innervation ([@bib136])                                                                                      
                                                                                                                        In vivo implantation ([@bib133]; [@bib119])                                                                  
                                                                                                                        Microfluidic access to apical/basal fluid reservoirs and fluid transport between organ systems ([@bib128])   
                                                                                                                        Organ-specific ECM ([@bib132]; [@bib142]; [@bib93])                                                          
                                                                                                                        Defined artificial ECMs may decrease lot-to-lot variability ([@bib40])                                       
                                                                                                                        Growth factor distribution within ECM gels for spatial control over growth and differentiation ([@bib138])   
                                                                                                                        Cell patterning for control over initial organoid shape and composition ([@bib88]; [@bib123])                
                                                                                                                        3D-printed gels amenable to perfusion with control over large-scale tissue structure ([@bib56])              
                                                                                                                        Morphological screening and sorting to enrich for correctly formed organoids ([@bib2])                       

Although pluripotent stem cells are a significant source for organoids, one concern is the immaturity of cells and tissues derived from these cells, because PSCs begin in a fetal-like state. Functional and developmental maturation of stem cells is an active area of research and has been pursued by techniques such as long-term culture, altered concentrations of growth factors and inhibitors, direct differentiation, and mechanical or electrical stimulation ([@bib24]; [@bib91]; [@bib78]; [@bib106]; [@bib118]; [@bib125]). In vivo maturation, typically by implantation into a mouse, has also been demonstrated to increase organoid maturity and can be used to generate adult-like human tissue and organoids ([@bib51]; [@bib133]; [@bib119]).

Similarly, accelerated aging in vitro will be necessary for PSC-derived organoids and useful for studying the functional consequences of age-associated damage. Accelerated aging experiments typically involve cells derived from progeric individuals ([@bib68]; [@bib80]) or expose cells to aging-associated stress, such as reactive oxygen species, inflammation, or radiation, which appear to phenocopy aspects of aging ([@bib87]; [@bib28]). With regard to aging experiments, organoid culture, as opposed to cell culture, has the advantage of increased stability. This stability has allowed culture periods as long as 60 wk ([@bib47]), which can be used to study chronological aging in vitro. For example, 120 d of culture of reconstituted human epidermis led to increased cellular senescence and morphological changes resembling those of chronological skin aging in vivo ([@bib32]). Furthermore, genomic stability has been reported to be higher in organoids than in traditional cell culture, as demonstrated by the use of organoid culture to clonally expand stem cells before mutational analysis ([@bib12]; [@bib52]; [@bib17]). Notably, organoid clonal expansion was also used to quantify the accumulation of mutations in adult ISCs with age ([@bib17]).

Primary cell and organoid culture remains highly sensitive to culture conditions. Support of the ISC niche, for example, was a revolutionary advance, permitting long-term expansion of intestinal organoids that once could be cultured for only a couple of weeks ([@bib94]). Other tissues, such as artery or ovary, can still only be cultured for only short times. Additionally, aging studies may be particularly sensitive to culture conditions. Numerous culture parameters that can phenocopy aspects of aging, such as replicative aging, oxygen tension, and free glucose, must be carefully controlled for. Finally, long-term culture and studying tissue homeostasis require the maintenance of growth-arrested organoids resembling the resting state of adult tissues. Identifying microenvironmental conditions to transition organoid tissues from a proliferative to a more mature, growth-arrested state would represent an important contribution to aging research.

As in vitro models increasingly seek to recapitulate complex tissue- and organ-level phenotypes, transport of oxygen and nutrients by diffusion becomes limiting. Air--liquid interfaces have been used to culture larger explants, but in general, vasculature will be necessary for the survival of most organoids over a couple hundred micrometers wide ([@bib4]), as well as useful for the study of aging-relevant phenotypes, such as metastasis and deterioration of the blood-brain barrier and glomerulus ([@bib120]; [@bib35]). Furthermore, vascularization has the potential to network organoids into systemic, multiorgan contexts that allow the exchange of hormones, cytokines, and metabolites, which have been implicated in aging in mice ([@bib131]). Incorporation into a systemic environment presents an opportunity to complement the strengths of organoid and in vivo platforms: organoids generated and manipulated in vitro can be implanted into mice, where they mature and integrate into the host vasculature ([@bib133]; [@bib119]). Such systems could be powerful tools to study the effects of an aged systemic environment on human tissues.

Similarly, microfluidics could increase the complexity of in vitro organoid systems while improving throughput and reproducibility. Multiorgan systems have been developed for the study of organ interactions via an in vivo-like sequential, organ-to-organ transfer of media, with a particular interest in drug interactions ([@bib128]). These devices could provide insight into how aging tissues affect other parts of the body. Additionally, microfluidic devices permit lumen access and control over millimeter-scale morphology. Although complex tissue structures, such as intestinal crypts and kidney nephrons, are readily generated by organoid self-organization ([@bib83]), the process can be highly heterogeneous, making assay readout complex or impossible. For example, reproducible kidney organoids with a channel-accessible central duct would enable key functional assays, namely permeability and urea concentration. Methods for micron-scale organization of cells within a tissue or microfluidic chamber ([@bib88]; [@bib123]; [@bib56]) could be used to create reproducible, high-throughput organoid assays for aging and other diseases.

Organoids are a powerful emerging tool for the study of human health and disease. Aging research has long needed a model with the practical advantages of simpler organisms and traditional cell culture, as well as the complexity required to model the tissue-level phenotypes that accompany aging. As researchers develop organotypic cultures of increasing complexity, it is becoming clear that organoids will enable the study of tissue-level, and even systems-level, phenotypes of aging. Human organoids have the potential to model the human body with unmatched fidelity. With time, new models will be developed and validated, significantly accelerating human aging research and the search for therapies that will improve human health and lifespan.

We thank Drs. Hao Li and Saul Villeda for their constructive feedback and discussion.

J.L. Hu is supported by the National Science Foundation Graduate Research Fellowship Program. M.A. LaBarge and M.E. Todhunter are supported by the Era of Hope Scholar Award from the Congressionally Directed Medical Research Programs Breast Cancer Research Program (BC141351), the National Institute on Aging (R01AG040081), and the City of Hope Center for Cancer and Aging. Z.J. Gartner is a Chan Zuckerberg Biohub investigator and is supported by an Era of Hope Scholar Award (BC123047), the Center for Cellular Construction (NSF DBI-1548297), and the National Institutes of Health (DP2HD080351).

The authors declare no competing financial interests.
